Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors - Wikidata - awgldk - TriplyDB

Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors

Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors

http://www.wikidata.org/entity/Q24548810

about

Single dose intravenous propacetamol or intravenous paracetamol for postoperative pain Single dose propacetamol or IV paracetamol for postoperative pain Single dose intravenous paracetamol or intravenous propacetamol for postoperative pain Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain Endogenous opiates and behavior: 2006 Bi- or multifunctional opioid peptide drugs.Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Opioid and melanocortin receptors: do they have overlapping pharmacophores?An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain.The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs.Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.A DFT and semiempirical model-based study of opioid receptor affinity and selectivity in a group of molecules with a morphine structural core Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav 2.2 Blocker Multitarget Ligands.Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.

P2860

Q24235989-348F78FE-220C-44E7-BA3F-4E15EFAF7C54 Q24243465-13D8B09C-E0E1-4C6B-A174-B7DE25DF7DC2 Q26471934-DEEB16E4-C4ED-4088-B69D-62750E63A015 Q26863769-C19252E2-C67B-49AF-9CA4-084E40F3DF9D Q28752585-8C1AB8A5-EAFD-4A83-B9B3-DA1D222DBA67 Q33767037-A8B06543-8DF5-442D-BFDB-06ADAD195AB7 Q34049320-476F0FD6-CC67-48F9-86CB-B56962A24B77 Q36274630-12D6F955-3243-43F5-A59A-843A1A75D785 Q36628300-AFEACA54-736B-48E3-B344-173D2B830F48 Q36628309-1E71C7CC-E76C-4D79-BA47-56236E500A88 Q36671480-4493A5E9-7054-4B23-89A0-87B3E280821C Q37012921-7F34DEF7-9C5F-4B77-958E-ED2E0778D347 Q37176219-6DDDBECB-B10E-48CB-B328-152080A0B678 Q37218872-25F141E4-EEEE-485D-8C1C-56DB1BA7F9A8 Q37312780-84D1C980-0556-41CD-8985-EFD4557CA2E9 Q37333022-792A0E7C-4F53-49C7-90F4-0A9A071B99D2 Q37365405-937BF498-B490-465D-B418-A274D08A5BEC Q37381216-385C6281-F2A6-4314-9A14-930CFDDDA587 Q37417012-FFA13B78-FA4C-47C8-BA1E-8026B157B734 Q37834512-425C9034-5BCD-45B9-8AFF-9B98ACAF13EE Q39157737-647C58E4-3722-4BD9-A5CC-E9358240ED21 Q41834469-87D27BAF-C24D-4933-8BE7-8DA04468FF74 Q44348169-01CBEEC8-DC08-48B2-9C41-4BEB427C5C21 Q55098217-399CC572-181C-4080-9CA9-43144C58DFC0

P2860

Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors

http://www.wikidata.org/entity/Q24548810

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Structure-activity relationshi ...... and cholecystokinin receptors

@ast

Structure-activity relationshi ...... and cholecystokinin receptors

@en

Structure-activity relationshi ...... and cholecystokinin receptors

@nl

type

label

Structure-activity relationshi ...... and cholecystokinin receptors

@ast

Structure-activity relationshi ...... and cholecystokinin receptors

@en

Structure-activity relationshi ...... and cholecystokinin receptors

@nl

prefLabel

Structure-activity relationshi ...... and cholecystokinin receptors

@ast

Structure-activity relationshi ...... and cholecystokinin receptors

@en

Structure-activity relationshi ...... and cholecystokinin receptors

@nl

P1433

Q24548810-F412958B-6F6C-49D6-B116-15146C8243B7

P1476

Q24548810-C808B246-B2AB-44D4-938C-2B17208ABC4A

P2093

Q24548810-512370B9-5672-4F21-91BC-8988F0526BE0

Q24548810-66A8E419-902A-4B7A-ABDD-A3EFF30A02BF

Q24548810-883831CD-84FF-4813-BD22-C881E7D165B7

Q24548810-D6D087C4-432D-430F-B940-526D85C64CCC

Q24548810-FD5DD54C-A258-4819-8870-5C135A3C4B30

Q24548810-FF494CC3-2BE7-4CF4-8FBE-83405D54D7E8

P2860

Q24548810-024DB3E9-03EB-43C8-BB53-E781DEEF16E5

Q24548810-0D3E82A9-52F2-4A52-9E55-8FBF6E60F3C8

Q24548810-1442AFCF-EAB7-4610-A6F4-C84B4F3B2E2C

Q24548810-15DE029D-D2F9-4713-9379-B193B97FD02C

Q24548810-1DFA2C82-60A1-4E3B-8512-384D07B00D25

Q24548810-217493B3-7290-447E-95A4-01BC2B415A6C

Q24548810-2E0B4C6B-6735-43AB-BD3D-4524FBACBA41

Q24548810-37952227-A25C-4E4A-A572-6CCB926FF390

Q24548810-3C1606A2-FEB6-46FC-96A9-DD0847813AE3

Q24548810-3DA19E67-D77D-4A5F-8511-284EAFCC2391

P304

Q24548810-DD8B9D96-6113-469B-815D-D5D35C26C526

P31

Q24548810-F83A0E32-6035-40B9-81A0-0317593E499D

P356

Q24548810-36DA12B2-C55D-4C04-9E2C-B0BB397362A4

P407

Q24548810-8C5F2B34-B9E8-41BF-9C72-9D1611FBB33E

P433

Q24548810-70D0A980-250C-46FD-B334-3E43B7E1BF4D

P478

Q24548810-136A6CA7-76AD-4F1B-8A0D-244D21335642

P50

Q24548810-09EB6402-5FD1-4D2D-B56C-64A77F262323

Q24548810-4DD79CE0-C85F-4C8F-9558-BDF3319C0847

P577

Q24548810-FD5E8AAB-FE0D-4A41-A195-96AD54CB7950

P5875

Q24548810-B9F7346C-E911-4422-80A0-90E0399AA0A6

P698

Q24548810-5A4B0005-841B-4F41-A9AA-7A2072A14D64

P921

Q24548810-9C2A484D-C16F-40A1-8136-08500A7894E3

Q24548810-A023B118-D02A-458E-8E43-8A8A4D742869

Q24548810-a28f4541-50fd-40ee-825c-cac7bb47470e

P932

Q24548810-8976ECF9-CAD2-417D-88EB-7C998A42DFFF

P356

P1433

Journal of Medicinal Chemistry

P1476

Structure-activity relationshi ...... and cholecystokinin receptors

@en

P2093

Hamid Badghisi

http://www.w3.org/2001/XMLSchema#string

Peg Davis

http://www.w3.org/2001/XMLSchema#string

Richard S Agnes

http://www.w3.org/2001/XMLSchema#string

Shou-Wu Ma

http://www.w3.org/2001/XMLSchema#string

Victor J Hruby

http://www.w3.org/2001/XMLSchema#string

Yeon Sun Lee

http://www.w3.org/2001/XMLSchema#string

P2860

CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

Distinct cholecystokinin receptors in brain and pancreas

International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors.

Cholecystokinin/opioid interactions.

A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.

Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin.

On the biologically active structures of cholecystokinin, little gastrin, and enkephalin in the gastrointestinal system.

The role of spinal cholecystokinin in chronic pain states.

Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.

P304

2868-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM050921Q

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7093865

http://www.w3.org/2001/XMLSchema#string

P698

16686530

http://www.w3.org/2001/XMLSchema#string

P921

Cholecystokinin

P932

1484468

http://www.w3.org/2001/XMLSchema#string